Apolipoprotein E genotype and concomitant clinical features in early-onset Alzheimer’s disease

J. Bronzova
Cornelia M. van Duijn
Louis M. Havekes
Peter de Knijff
Christine Van Broeckhoven
Albert Hofman

Received: 8 June 1995
Received in revised form: 15 August 1995
Accepted: 3 October 1995

J. Bronzova - C. M. van Duijn (✉)
A. Hofman
Department of Epidemiology
& Biostatistics and the Netherlands
Institute for Health Sciences,
Erasmus University Medical School,
Rotterdam, PO Box 1738,
NL-3000 DR Rotterdam, The Netherlands
Tel.: 31 10 4087394
Fax: 31 10 4365933
E-mail: duijn@epib.fgg.eur.nl

J. Bronzova
The Laboratory of Molecular Pathology,
University Hospital of Obstetrics
and Gynaecology, Medical University,
Sofia, Bulgaria

L. M. Havekes · P. de Knijff
TNO, Institute of Prevention and Health,
Gautius Laboratory, Leiden,
The Netherlands

C. Van Broeckhoven
The Neurogenetics Laboratory,
Flemish Institute of Biotechnology,
Born-Bunge Foundation,
Department of Biochemistry,
University of Antwerp, Antwerp,
Belgium

Abstract We have studied the relationship between the apolipoprotein E gene (APOE) and the development of myoclonus, tremors, rigidity and seizures in 168 patients with probable early-onset Alzheimer’s disease (AD). There was a statistically significantly lower risk of tremor for carriers of the ε4 allele of APOE. This allele was also associated with an increased risk of myoclonus. Our findings suggest that there may be differences in progression and clinical appearance in early-onset AD related to the APOE genotype.

Key words Alzheimer disease · Apolipoprotein E gene

Introduction

Alzheimer’s disease (AD) is a clinically heterogeneous disorder. It is often accompanied by the development of extrapyramidal signs [13], myoclonus [8, 13] and seizures [8]. These concomitant clinical features in AD have been associated with a more rapid cognitive decline and increased mortality. Therefore, it has been suggested that these features may be markers of disease progression [13]. AD has been associated with apolipoprotein E (apoE) [14]. An increased risk of late-onset and early-onset AD has been observed for carriers of the ε4 allele of the apoE gene (APOE*4) compared with patients who carry two copies of the wild-type or normal allele ε3 (APOE*3) [3, 14, 15]. The association with the ε2 allele of the apoE gene (APOE*2) is less clear. Although a number of studies have reported a protective effect of the APOE*2 allele on the risk of AD [3, 4], others have reported an increased AD risk for carriers of this allele [12, 16].

We have shown previously that the APOE gene is associated with survival of patients with early-onset AD [16]. Here we present a study on the role of the APOE gene in the development of concomitant clinical features in AD. The aim of this analysis was to examine whether the APOE*4 and APOE*2 allele are associated with a distinct clinical expression.

Patients and methods

Patients were derived from a population-based study of early-onset AD. Details concerning the study design have been published elsewhere [15, 16]. The protocol of the study has been reviewed by the medical ethics committee of the Erasmus University and Academic Hospital Dijkzigt. The series comprised all patients from two
areas of the Netherlands, in whom the onset of AD was at age 65 years or earlier and who were diagnosed as having AD in the period January 1980 to July 1987. The diagnosis of probable early-onset AD was verified according to a standard protocol similar to NINCDS-ADRDA criteria. Information was available for 198 (99%) of the 201 patients who met the inclusion criteria. Informed consent was obtained from all patients. For all patients, detailed data on family history of dementia in first-, second- and third-degree relatives were collected [15]. These data were always verified by a sibling of the patient. The family history of subjects with no first-degree relatives with dementia was classified as negative and of those with at least one first-degree relative with dementia as positive. APOE typing could be performed in 175 (88%) of the patients [15].

At entrance into the study, data on medication and on the occurrence of clinical features including myoclonus, tremor, rigidity and seizures were collected through medical records from the general hospital where the patient was diagnosed and from the nursing home for those patients that were institutionalized. At follow-up in 1990, medical records from general hospitals and nursing homes were up-dated for all patients. The protocol of data collection and the relationship of the clinical features to mortality have been described elsewhere [11]. The present analysis is based on the presence of clinical features at diagnosis or their occurrence during the follow-up of the patients up to 1990. We have considered only clinical features that were not related to medication. The mean period of follow-up after diagnosis was 6 years (range 2–11; SD = 2). Data on the clinical course were available for 168 (96%) of the 175 patients in whom APOE was typed.

All statistical analyses were carried out with the Epidemiological Graphics Estimation and Testing package (EGRET). To adjust for censoring of the data which occurred because not every patient was followed until death, Cox’s proportional hazards model was used to estimate the effect of the APOE gene on the occurrence of a clinical feature [6]. In addition, we have adjusted all analyses for left truncation, which occurred because not all patients were included in our study at the time of diagnosis [10].

Results

General characteristics of the 168 patients are given in Table 1 for APOE*3 homozygotes (APOE3E3), APOE*4 and APOE*2 carriers. Among APOE*2 carriers, there were significantly (P < 0.05) more men (50%) compared with APOE*4 (31%) and APOE3E3 (30%) carriers. A family history of dementia was found more often among carriers of the APOE*4 allele (P < 0.05). APOE genotype was not associated with age at onset. Also, the score on the Clinical Dementia Rating (CDR) scale [9] at diagnosis was not associated with the APOE*4 allele [relative risk = 0.7; 95% confidence interval (CI) 0.3–1.5; reference APOE3E3] or the APOE*2 allele (relative risk = 1.1; 95% CI 0.3–3.3; reference APOE3E3).

Table 2 shows the risk of concomitant clinical features by APOE genotype. APOE*4 carriers had a significant, 2.2-fold higher risk of myoclonus compared with carriers of the APOE3E3 genotype (95% CI: 1.1–4.4). A non-significant increase in risk of myoclonus was found for APOE*2 carriers. APOE*4 carriers had a significantly lower risk of tremors. No significant association was observed between the APOE genotype and the risk of rigidity and seizures. The risk of myoclonus and tremors by APOE genotype is plotted in Fig. 1. Although at each point in time after diagnosis the risk of myoclonus was higher in APOE*4 and APOE*2 carriers than in APOE3E3 carriers, in the 11 years of follow-up 55% (95% CI: 35–78%) of the APOE3E3 carriers developed myoclonus. After 3 years of follow-up, the risk of tremors was consistently lower in APOE*4 than in APOE*2 and APOE3E3 carriers.

When stratifying for family history of dementia, the association of the APOE*4 and APOE*2 allele with myoclonus was strongest in those with a negative family history of dementia. The risk of myoclonus was 2.8 (95% CI: 1.0–7.3) times greater for APOE*4 carriers and 2.3 (95% CI: 0.7–7.3) times greater for APOE*2 carriers when compared to APOE3E3 carriers (not in table). Among those with a positive family history, there was a 1.5-fold (95% CI: 0.6–3.8) increased risk associated with the APOE*4 allele and a 1.4-fold (95% CI: 0.4–5.8) increase with the APOE*2 allele. There was no evidence for effect modification after stratifying the data by gender.

### Table 1 Characteristics of the 168 patients with early-onset Alzheimer’s disease (AD)

<table>
<thead>
<tr>
<th>Clinical feature</th>
<th>APOE*3E3</th>
<th>APOE*4 carriers</th>
<th>APOE*2 carriers</th>
</tr>
</thead>
<tbody>
<tr>
<td>n = 57 carriers</td>
<td>n = 88 carriers</td>
<td>n = 24 carriers</td>
<td></td>
</tr>
</tbody>
</table>

| Men | 17 (30%) | 27 (31%) | 12 (50%) |
| Family history positive | 29 (51%) | 61 (69%) | 12 (50%) |
| Mean onset age (SD) | 57 (6) | 58 (6) | 56 (6) |

*One subject with the APOE2E4 genotype is included as an APOE*4 as well as an APOE*2 carrier.

### Table 2 The relative risk (95% confidence interval) of myoclonus, tremor, rigidity and seizures in early-onset AD for APOE*4 and APOE*2 carriers compared with the risk for carriers of the APOE3E3 genotype

<table>
<thead>
<tr>
<th>Clinical feature</th>
<th>APOE*3E3</th>
<th>APOE*4 carriers</th>
<th>APOE*2 carriers</th>
</tr>
</thead>
<tbody>
<tr>
<td>n = 14 carriers</td>
<td>n = 23 carriers</td>
<td>n = 9 carriers</td>
<td></td>
</tr>
<tr>
<td>Myoclonus</td>
<td>1</td>
<td>2.2</td>
<td>1.9</td>
</tr>
<tr>
<td>Reference</td>
<td>(1.1–4.4)</td>
<td>(0.8–4.9)</td>
<td></td>
</tr>
<tr>
<td>n = 14 carriers</td>
<td>n = 21 carriers</td>
<td>n = 7 carriers</td>
<td></td>
</tr>
<tr>
<td>Tremor</td>
<td>1</td>
<td>0.4</td>
<td>1.4</td>
</tr>
<tr>
<td>Reference</td>
<td>(0.2–0.8)</td>
<td>(0.6–3.3)</td>
<td></td>
</tr>
<tr>
<td>n = 22 carriers</td>
<td>n = 31 carriers</td>
<td>n = 9 carriers</td>
<td></td>
</tr>
<tr>
<td>Rigidity</td>
<td>1</td>
<td>0.7</td>
<td>0.8</td>
</tr>
<tr>
<td>Reference</td>
<td>(0.4–1.3)</td>
<td>(0.4–1.9)</td>
<td></td>
</tr>
<tr>
<td>n = 30 carriers</td>
<td>n = 42 carriers</td>
<td>n = 12 carriers</td>
<td></td>
</tr>
<tr>
<td>Seizures</td>
<td>1</td>
<td>0.8</td>
<td>1.1</td>
</tr>
<tr>
<td>Reference</td>
<td>(0.5–1.4)</td>
<td>(0.5–2.2)</td>
<td></td>
</tr>
</tbody>
</table>

*One subject with the APOE2E4 genotype is included as an APOE*4 as well as an APOE*2 carrier.

*The number of patients who developed the clinical feature over time.
of myoclonus or seizures [11]. This suggests that tremor, one of the features associated with APOE, was suitable distinguished by the participating physicians from the other associated feature, myoclonus. Also, it is important to note that in order to bias our results the misclassification in the clinical features must have occurred differentially in APOE3E3. APOE*4 and APOE*2 carriers in order to introduce an artificial relationship. It is unlikely that this has happened systematically, as the nursing home staff were not aware of the patient’s APOE genotype. Most likely, bias due to misdiagnosis has occurred randomly and independent of the APOE genotype in our study. The effect of such misclassification is most likely that existing relationships are diminished rather than non-existing associations being created.

Our findings suggest that there may be differences in the clinical course of early-onset AD related to the APOE genotype. One earlier study failed to show an association [1]. However, that study was based on late-onset AD and the number of patients was small (n = 60) while the follow-up period was limited (3 years) [1]. Our study shows that APOE*4 carriers have a significantly decreased risk of developing tremors. Although there is considerable controversy concerning the role of APOE in the survival of AD patients [2, 5], our study and those of others suggest that the APOE*4 allele is associated with a slower progression of AD and a reduced risk of mortality [1, 7, 16]. Our earlier finding of a lower mortality for early-onset AD patients who carry the APOE*4 allele [16] agrees with the lower risk of tremors, because the latter probably indicate an advanced stage of AD [13]. There are two possible explanations for these findings. Firstly, the diagnosis of AD occurs earlier in APOE*4 carriers than in other patients, leading to an artificially prolonged survival. Secondly, the APOE*4 allele is truly associated with a slow progression of AD. The first explanation is plausible, e.g. because APOE*4 carriers are more likely to have a positive family history [15] or a history of cardiovascular disease and may be more alert when initial symptoms appear. However, in our population the age of onset and the severity of the dementia at diagnosis as measured by the CDR score was similar in patients with and without the APOE*4 allele [15]. Adjusting the analysis for the CDR score at diagnosis or the duration of dementia at diagnosis did not change any of our conclusions, suggesting that the explanation of a relatively early diagnosis in APOE*4 carriers is unlikely. In addition, our finding that the risk of myoclonus was significantly increased for APOE*4 carriers challenges this hypothesis, since the occurrence of both tremors and myoclonus has been shown to indicate advanced stages of AD [13].

The increased risk of myoclonus for APOE*4 carriers cannot be explained by disease progression but suggests an unusual early expression of myoclonus in early-onset AD patients with the APOE*4 allele. The hypothesis of a distinct clinical appearance of patients is further sup-
ported by the finding that the association was strongest in those with a negative family history. It is important to note that the occurrence of myoclonus was not limited to APOE*4 carriers. APOE3E3 carriers may also develop myoclonus, albeit at a later stage. The finding that carriers of the APOE*2 allele have a risk of tremors similar to that of carriers of the APOE3E3 genotype, while at the same time the risk of myoclonus for APOE*2 carriers is similar to that for APOE*4 carriers, seems contradictory. However, our findings on the APOE*2 allele are based on a small number of patients.

This is the first study to suggest that there may be differences in progression and clinical appearance in early-onset AD related to the APOE genotype. An important advantage of our study is the population-based design in which patients have been followed for an extended period. However, our findings are based on a specific subgroup of AD patients with an early onset of AD. Further, we have not collected data on the occurrence of the features under study by a standardized clinical examination. Our findings therefore remain to be confirmed by other studies on the clinical course of AD.

Acknowledgements This study was supported by the Netherlands Organization for Scientific Research (NWO), the Netherlands Institute for Health Sciences (NIHES), the Euredom EC Concerted Action on dementia, the Flemish Biotechnology Program and the Belgian National Fund for Scientific Research (NSFR). C.V.B. is a research associate of the NFSR Belgium. We thank Drs. Wim Schulte, Teun Tanja, Rob Haaxma, Arie Lameris, Rolf Saan for assisting with case diagnosis and Helen de Bruijn, Micheline de Haes, Jeanette Kamman, Hilda Kornman, Hanneke van Meurs and Caroline Valkenburg for their help in data collection. Hans van der Boom, Marc Cruts, Anita Wehnert and Joke De Voecht are thanked for apolipoprotein E typing.

References